Asert

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Asert

Quick Facts

Property Description
Active Ingredient Sertraline
Form Typically a tablet or capsule (Solid Oral Form)
Pharmacological Class Selective Serotonin Reuptake Inhibitor (SSRI)
Origin Synthetic (laboratory-created)
General Purpose To support emotional and mental equilibrium

What Type of Medication is Asert and How is it Classified?

Asert is the brand name for a medication containing the active pharmaceutical ingredient Sertraline. This compound is specifically classified as a Selective Serotonin Reuptake Inhibitor (SSRI), a class of medication used to manage and regulate chemical activity within the nervous system. SSRIs, as a class, are designed to inhibit the reuptake of serotonin.

The active component, Sertraline, is synthesized in a laboratory setting, meaning its origin is not natural. Asert is manufactured in a solid oral form (tablets or capsules) and is recognized by medical professionals as a treatment option within its class. Unlike some other SSRIs that are restricted to adults, Asert is clinically recognized for use across a broader patient group, including specific pediatric applications.


What is the General Therapeutic Purpose of Asert?

The general therapeutic purpose of Asert is to help the body maintain emotional and mental equilibrium by sustaining a functional balance of key neurochemicals in the brain. It is designed to be a regulatory treatment requiring consistent, routine use rather than an immediate-acting compound.

By modulating the available levels of serotonin, Asert aims to support the overall stability of the central nervous system. The primary mechanism and general benefit of these compounds is to produce sustained regulation of affective symptoms, rather than immediate relief. The overall goal of taking Asert is to promote long-term stability and foster a balanced mental state over time, allowing individuals to navigate everyday life with greater resilience.

What side effects are possible with Asert?

Possible Side Effects and Safety Information

The official safety profile for Asert (Sertraline) is structured by government regulatory bodies to classify potential adverse reactions based on their reported frequency and the specific physiological system affected. These classifications provide a clear, high-level overview of the drug's safety characteristics.

Regulatory Classification of Adverse Reactions

Side effects are grouped by the estimated likelihood of occurrence as observed in clinical data:

Frequency Classification Examples of Reactions
Very Common (ge 1/10) Nausea, Insomnia, Dry mouth, Diarrhea, Headache
Common (ge 1/100 to < 1/10) Dizziness, Somnolence, Fatigue, Tremor, Increased sweating, Ejaculation failure (males)
Uncommon to Rare Palpitations, Hypomania, Mania, Serotonin Syndrome, Severe Cutaneous Reactions

Adverse effects are documented across various System-Organ Classes, including Gastrointestinal disorders (e.g., vomiting, constipation), Nervous system disorders, and Psychiatric disorders. Sexual dysfunction, such as ejaculation failure and decreased libido, is consistently listed as a common reaction.

Serious Safety Information and Constraints

Regulatory documents highlight a documented risk of Suicidal Ideation and Behavior, particularly at the initiation of therapy and following dose changes, especially in young adults and adolescents. Clinically significant reactions, such as Serotonin Syndrome, Hemorrhagic Events, and Hyponatremia (low sodium levels), are also noted as serious concerns.

Specific safety considerations exist for certain populations. Older adults are documented as having an increased risk of hyponatremia. Furthermore, Asert is contraindicated for use in individuals concurrently taking Monoamine Oxidase Inhibitors (MAOIs).

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Asert (Sertraline) by outlining specific, documented clinical manifestations and mandated emergency actions. Overdose presentations commonly include somnolence, confusion, dizziness, tremor, agitation, fever, and gastrointestinal effects like vomiting. The officially documented severe and life-threatening outcomes include seizures, progression to coma, and the development of Serotonin Syndrome.

Of critical concern is the potential for cardiovascular toxicity, particularly QTc interval prolongation, which necessitates acute care. Regulatory labeling mandates that any suspected overdosage must be medically treated aggressively. Patients or caregivers must contact emergency services immediately if severe symptoms such as collapse, trouble breathing, or an inability to be awakened occur. The risk of severe outcomes is often heightened by the co-ingestion of other drugs or alcohol.

There is no specific antidote known for Sertraline overdose. Management focuses on general symptomatic and supportive measures, including continuous ECG monitoring for cardiac activity. The use of activated charcoal may be considered, but procedures like emesis induction are not recommended, as stated in the prescribing information.

Therapeutic Uses of Asert

What Asert treats: Main Uses and Benefits

Asert (Sertraline) is generally applied across therapeutic domains where supportive symptom management is needed, helping to ease the overall symptom burden that may interfere with functional stability. This medication is relevant in clinical settings that involve acute or unstable symptom patterns.

The medication is applied within therapeutic domains that include conditions characterized by periods of heightened symptoms, such as Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Social Anxiety Disorder, Post-Traumatic Stress Disorder (PTSD), and Premenstrual Dysphoric Disorder (PMDD). It is applied in addressing symptom clusters that may become intense, including the management of persistent low mood, excessive anxiety, intrusive thoughts, and cyclical mood volatility.

This supportive approach is generally applied during phases of increased distress, and may provide relief when symptoms become temporarily overwhelming.

“This medication is relevant for addressing symptoms related to heightened physiological activity, such as pronounced anxiety, panic attacks, and trauma-related hyperarousal.”

This may provide supportive relief and assists with maintaining functional stability, which contributes to improved comfort during symptomatic periods.

Quick Fact: Relief for Key Symptom Domains
Symptom Focus Persistent low mood, panic attacks, social fear, intrusive thoughts, and premenstrual irritability.
Context of Use Chronic management and support during episodic or recurrent periods of heightened distress.
Primary Benefit Helps maintain a sense of stability and assists with easing the overall symptom load.

Regulatory References

  1. NIH MedlinePlus Drug Information on Sertraline

Eligibility and Restrictions for Use

Official Eligibility Rules for Asert (Sertraline)

Official regulatory documents define specific populations who can and cannot use Asert, the brand name for sertraline. Use is contraindicated for patients who are currently taking or have recently stopped a Monoamine Oxidase Inhibitor (MAOI) or are taking the medication Pimozide.


Population Eligibility Regulatory Status Documentation Basis
Adults (18+ years) Approved for all labeled conditions. Established Use
Pediatric (6–17 years) Restricted to Obsessive-Compulsive Disorder (OCD) only. Safety/Efficacy Established for OCD
Children under 6 Use Not Established. Insufficient Data

Condition-Based Restrictions:

  • Hepatic Impairment: Use is contraindicated or not recommended in severe hepatic impairment. Patients with mild hepatic impairment may be eligible but require caution and/or a lower dose according to labeling.
  • Pregnancy/Lactation: Use is not recommended unless the benefit outweighs the risk. Specific caution is noted for third-trimester use due to the documented risk of neonatal complications, such as Persistent Pulmonary Hypertension of the Newborn (PPHN).
  • Other Restrictions: Patients with a history of unstable epilepsy or a risk of angle-closure glaucoma must use the medicine with caution or are advised to avoid use.

What should I know about interactions with other medicines?

Asert (sertraline) interacts with a variety of medications, primarily through mechanisms that enhance serotonin activity or affect blood clotting, necessitating careful co-administration or avoidance.

Contraindicated Combinations

  • Monoamine Oxidase Inhibitors (MAOIs): Co-administration with MAOIs, including linezolid (an antibiotic with MAOI activity) and intravenous methylene blue, is strictly contraindicated. This combination significantly raises the risk of Serotonin Syndrome, a potentially life-threatening condition. A minimum 14-day washout period is required when switching between Asert and any MAOI.
  • Pimozide: Concomitant use with the antipsychotic pimozide is contraindicated, as Asert can increase pimozide levels in the body, which may lead to serious cardiac rhythm abnormalities.
  • Disulfiram: The oral liquid formulation of Asert is contraindicated with disulfiram due to the oral solution’s alcohol content, which can cause an unpleasant disulfiram-alcohol reaction.

Use with Caution

Product Category Interaction Mechanism & Risk
Serotonergic Agents (e.g., triptans, fentanyl, other SSRIs, SNRIs) Increased risk of Serotonin Syndrome through additive serotonin effects.
Anticoagulants/Antiplatelets (e.g., warfarin, NSAIDs, aspirin) Increased risk of abnormal bleeding (including gastrointestinal) due to sertraline's effect on platelet aggregation. Close monitoring is necessary.
CYP2D6 Substrates (e.g., certain TCAs, risperidone) Asert is a moderate inhibitor of the CYP2D6 enzyme, which can increase the concentration and risk of side effects of medications metabolized by this pathway.
Phenytoin Co-administration may increase phenytoin levels, requiring careful monitoring of plasma levels.

Mechanism of Action

Selective Serotonin Reuptake Inhibition

Asert acts as a highly selective inhibitor of the Serotonin Transporter (SERT) protein on presynaptic neurons. By binding to SERT, the drug blocks the reuptake of the neurotransmitter serotonin (5-HT) from the synaptic cleft. This action increases the concentration of 5-HT in the synapse, leading to sustained presence and subsequent engagement of postsynaptic receptors.

Neuroplastic Cascade and Systemic Modulation

Sustained elevation of synaptic serotonin triggers neuroadaptive changes over several weeks, including the desensitization of specific serotonin receptors. This modulation affects the activity of central systems associated with emotional and stress response. The targeted CNS effect alters neural signaling patterns, influencing physiological processes including neuroendocrine feedback and homeostatic set points via the Hypothalamic-Pituitary-Adrenal (HPA) axis.

Dosage and Administration Information

How Asert is Used

Asert (Sertraline) administration follows established guidelines, establishing specific patterns for dosing, frequency, and preparation. The medication is intended for oral administration. It is available as a tablet (25 mg, 50 mg, 100 mg), a capsule (150 mg, 200 mg), and an oral concentrate solution (20 mg/mL).


Official Administration Protocol

Use of Asert is structured as a sustained, long-term regimen taken once daily. Tablets may be taken with or without food. The starting dose varies by indication; for example, treatment for Major Depressive Disorder (MDD) typically begins at 50 mg once daily, while conditions like Panic Disorder (PD) start lower at 25 mg, increasing to 50 mg after one week.

Dosing Principle Details
Dose Titration Dosage adjustments are made in increments of 25 mg or 50 mg, at intervals of at least one week, up to a maximum of 200 mg daily.
PMDD Schedule The medication may be taken continuously (daily) or intermittently, beginning 14 days prior to menstruation.
Hepatic Adjustment For mild hepatic impairment, the starting and maximum dosage is half the normal dose.

Preparation and Discontinuation

The oral concentrate solution requires mandatory dilution before intake, using only approved liquids, such as water or specific sodas, and must be consumed immediately after mixing. Discontinuation of Asert, regardless of the duration of use, requires a gradual dose reduction (tapering) over a period of several weeks, as noted in prescribing information. There are no explicit instructions for handling a missed dose, reinforcing the need for consistent once-daily administration.

Recent Clinical Evidence

Research evidence / Overview of Studies for Asert (Sertraline)

This section provides an overview of the official research landscape for Asert (Sertraline), based on studies such as randomized controlled trials (RCTs) and analyses reviewed by health regulators. The summary describes the types of research conducted, the outcomes monitored, and where limitations or uncertainties in the evidence exist. Research provides context but not individual predictions; findings describe group patterns, not personal outcomes.


Evidence for Use in Major Depressive Disorder (MDD) and Prevention of Recurrence

Research exploring short-term symptom changes in Major Depressive Disorder (MDD) primarily involved Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, typically lasting from 6 to 12 weeks. Researchers monitored outcomes related to functional imbalance, specifically looking at changes in the intensity of depressive symptoms using standardized scales and observing how often a complete period of symptom absence (remission) was achieved. Long-term maintenance studies tracked patients for up to 18 months or more, monitoring recurrence following initial short-term change.

Evidence is limited for the full functional stability beyond the trial observation periods. Results apply only to the populations studied, and data for certain groups, such as those with mild-to-moderate symptoms treated solely in primary care settings, do not provide a clear indication of magnitude. Research is ongoing to better characterize these outcomes over extended time intervals.


Evidence for Use in Obsessive-Compulsive Disorder (OCD) and Social Anxiety Disorder (SAD)

Asert was studied for Obsessive-Compulsive Disorder (OCD) and Social Anxiety Disorder (SAD) in numerous Randomized Controlled Trials across various dose strategies. Studies examined symptom intensity over short-term periods, typically 8 to 12 weeks, focusing on outcomes capturing phases of heightened symptom activity. The populations included adults and specific research examined pediatric patients (children and adolescents) with OCD.

A key limitation noted is that the research does not consistently describe a proportional relationship between higher doses and measured outcomes across all studies. While studies were conducted for both adults and children, the follow-up durations were limited for understanding the long-term observation of symptoms in pediatric patients over many years.

Key Studies & References

  1. Efficacy and Safety of Sertraline Treatment of Posttraumatic Stress Disorder (Adult RCT)
  2. Sertraline as a treatment for PTSD: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Asert (FAQ)


Q: Does Asert cause weight gain?

A: Official information from regulatory documents indicates that weight changes have been observed in clinical studies for Asert. Both weight gain and weight loss have been reported, although decreased weight has been noted in certain patient groups, such as children. Regulatory documents indicate that weight changes have been reported as a possible effect.


Q: How long does it typically take to start noticing the effects of Asert?

A: Asert works by triggering neuroadaptive changes in the brain that require sustained treatment. While patients may experience some initial changes in energy, sleep, or appetite within the first one to two weeks, the time required for the medication to reach its full effect and help stabilize symptoms often takes several weeks, commonly ranging from four to eight weeks, though this varies by individual.


Q: Is Asert addictive or habit-forming?

A: Asert is a Selective Serotonin Reuptake Inhibitor (SSRI) and is not classified as a controlled substance by regulatory bodies, meaning it is not considered to have a significant potential for abuse or addiction. However, regulatory documents advise that discontinuing the medication requires a gradual dose reduction, known as tapering, to help reduce the risk of discontinuation symptoms.


Q: What is the experience like when stopping Asert?

A: Stopping Asert, particularly if done abruptly, may be associated with symptoms referred to as discontinuation syndrome. These effects can include dizziness, nausea, headache, anxiety, or sensory disturbances, such as electric shock-like sensations. Regulatory agencies advise a gradual dose reduction over several weeks to minimize the occurrence and severity of these effects.


Q: What time of day is Asert usually recommended to be taken?

A: Official administration instructions state that Asert is typically taken once daily. Regulatory documents do not mandate a specific time of day (morning or evening). Regulatory information indicates the medication is intended to be taken consistently at the same time each day to help maintain stable levels in the body.


Q: Are the research studies on Asert long-term or short-term?

A: The official research base for Asert includes both short-term studies and long-term maintenance studies. Short-term trials typically examine initial changes over a period of 6 to 12 weeks. Long-term studies have been conducted to monitor recurrence of symptoms for up to 18 months or more to assess sustained symptom regulation.


Q: Can Asert affect liver function?

A: Yes, regulatory documents indicate that Asert may affect liver function. Use is not recommended in cases of severe liver impairment, and the medication's processing is altered in people with chronic mild liver impairment. Liver enzyme elevations have also been reported as a documented side effect.


Q: Does Asert require special monitoring or blood tests?

A: While routine monitoring for all users is not generally required, official information notes that certain circumstances may necessitate monitoring. For instance, specific blood tests may be needed to check for hyponatremia (low sodium levels), particularly in older adults, or when Asert is taken alongside certain interacting medications.


Q: What are the most common side effects people talk about with Asert?

A: Official regulatory data classifies the most commonly reported side effects as 'Very Common,' meaning they are expected to occur in 1 out of every 10 patients or more. These often discussed effects primarily include gastrointestinal issues, such as nausea and diarrhea, and nervous system effects like insomnia and headache.


Q: Is Asert available as a generic drug?

A: Yes, the active pharmaceutical ingredient in Asert, Sertraline, is widely available as a generic medication. The generic form is manufactured by various companies and is considered an alternative to the brand-name product.


Q: Does Asert make people feel emotionally numb?

A: Although the phrase 'emotional numbness' is not standard medical terminology, official documents list adverse reactions in the psychiatric disorders category. These reports include reduced interest in activities (apathy), which may align with a general feeling of emotional blunting as described in medical discussions.


Q: Can men and women expect different effects from Asert?

A: Official regulatory documents list some side effects with specific gender prevalence. For example, ejaculation failure is noted as a common side effect observed in males. However, the general therapeutic effects for the conditions it treats are described for the population as a whole.


Q: Can Asert make other health conditions worse?

A: Regulatory documents list specific existing health conditions where Asert must be used with caution or is contraindicated (not allowed). These include unstable epilepsy, a risk of angle-closure glaucoma, and severe liver impairment, as taking the medication may increase the risk of complications related to these conditions.


Q: Is it true that Asert has been studied for uses beyond its main approval?

A: Official regulatory documents only describe and provide evidence for the medication's approved uses, such as Major Depressive Disorder and Obsessive-Compulsive Disorder. Regulatory agencies prohibit the promotion or discussion of any uses that have not been fully reviewed and granted approval.


Q: Is Asert a controlled substance?

A: No, Asert (Sertraline) is a Selective Serotonin Reuptake Inhibitor (SSRI) and is not classified as a controlled substance under regulatory scheduling systems. Indicating that the drug is not considered to have a significant potential for dependence or abuse.


Q: Does taking Asert affect blood pressure?

A: Official regulatory documents list adverse reactions that may relate to cardiovascular function. Palpitations (abnormal heart rhythm) are listed as a possible side effect. Furthermore, in rare cases of Serotonin Syndrome, high blood pressure and rapid heart rate are noted as potential symptoms.


Q: Are there any known interactions between Asert and herbal remedies?

A: Official drug documents explicitly state that co-administration of Asert with the herbal supplement St. John's Wort is not recommended. This combination is noted to increase the risk of Serotonin Syndrome due to the additive effects on serotonin activity.


Q: Why is Asert sometimes started at a lower amount and then increased?

A: The official administration protocol involves starting at a lower amount and then gradually increasing (titrating) the dose over a period of several weeks. This regulated method is used to allow the patient’s body to adjust to the medication, which can help improve tolerability and minimize the occurrence of initial side effects.


Q: What happens if I miss several doses of Asert?

A: If a patient misses several consecutive doses of Asert, the level of the drug in the body may drop significantly. This reduction can lead to the onset of discontinuation symptoms, such as irritability, dizziness, or a return of the original symptoms. A healthcare provider can offer guidance on managing a return to the regular dosing schedule.


Q: What percentage of people experience side effects with Asert?

A: Official regulatory documents classify adverse reactions by their likelihood of occurrence, such as 'Very Common' (occurring in 1 out of 10 people or more). While an exact single percentage for the incidence of all possible side effects is not published, official study summaries indicate a substantial number of patients experience at least one non-serious adverse event.


Q: Is Asert a mood stabilizer?

A: No, Asert is not formally classified as a mood stabilizer. Its pharmacological classification is a Selective Serotonin Reuptake Inhibitor (SSRI), which is a modern class of medication used to help regulate chemical activity within the nervous system.


Q: Does Asert have a 'black box' warning, and what does that mean?

A: Yes, regulatory documents for Asert carry a Boxed Warning, which is the strongest warning the FDA requires for prescription medicines. This warning highlights the documented increased risk of suicidal thoughts and behaviors, particularly in children, adolescents, and young adults (up to age 24), especially when starting treatment or when the dose is changed.


Q: Will I need to change my diet while taking Asert?

A: Official regulatory documents generally do not mandate a change to a patient's overall diet. The medication may be taken with or without food. However, official warnings advise caution regarding the consumption of alcohol due to potential additive central nervous system effects.


Q: Is Asert generally considered well-tolerated?

A: Official regulatory reviews indicate that the safety and tolerability profile of Asert has been established across numerous clinical trials. While side effects are a common occurrence, most are classified as mild-to-moderate and tend to decrease with continued use, supporting its classification as a standard treatment option.

How should Asert be stored and disposed of?

How to Store and Dispose of Asert

Storage of Asert (sertraline) must adhere strictly to officially mandated conditions to ensure product integrity and stability.

Storage Requirements

Requirement Description
Temperature Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F).
Protection Keep the medication in its original, tightly closed container and protect it from excess heat and moisture.
Child Safety The product must always be stored securely and kept out of the reach of children.

Disposal Instructions

Unused or expired Asert should be discarded according to regulatory guidelines. The preferred method is to utilize a drug take-back program. If a program is unavailable, the medication can be mixed with an undesirable substance (like dirt or coffee grounds) and placed in a sealed bag for disposal in household trash. Do not flush Asert down the toilet or pour it down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Asert found in:

A-Z Index: